Arab Finance: Deputy Prime Minister for Industrial Development and Minister of Industry and Transport Kamel El-Wazir met with representatives of 29 French companies and institutions and discussed investment opportunities in Egypt, according to a statement.
The companies are specialized in renewable energy, food industries, pharmaceuticals, construction and real estate, water and waste management, digital business solutions, communications, and logistics, among others.
This aligns with the ministry’s plan to advance the industry and transportation sectors under President Abdel Fattah El-Sisi's directives to achieve sustainable development growth in Egypt.
El-Wazir also reviewed the companies’ future plans for injecting new investments or expanding their investments in the Egyptian market.
These strategies include Airbus Company's plan to deepen local manufacturing in the field of helicopter manufacturing and maintenance. It also seeks to manufacture helicopters for tourism and medical transportation in Egypt.
Furthermore, Capgemini plans to develop digital systems and information technology, while Société Générale’s aims to finance several transportation projects in Egypt in the coming period.
The meeting also reviewed CDS's plan to enhance joint cooperation in coincide with the ministry’s plans for signaling systems on Egyptian railway lines in several projects, such as the Al-Ferdan-Bir El-Abd-Al-Arish-Taba railway project.
The minister also addressed the partnership with Italian company MERMEC, noting that all the required supplies for this project will be manufactured within Egypt.
Additionally, the meeting touched upon Artelia Group's plans to participate in French government-funded transportation projects, such as the Alexandria tram project, airport engineering projects, and metro projects.
Finally, Servier Pharmaceuticals aims to expand its factory in 6th of October City, which specializes in the production of medicines for chronic diseases, such as heart disease, high blood pressure, blood vessels, and diabetes.
This is part of the company's plan to double its production, in addition to producing cancer medicines.